[144] Doximity, Inc. SEC Filing

Rhea-AI Filing Summary

Ionis Pharmaceuticals (IONS) – CEO Form 4 insider transaction dated 07/30/25

Chief Executive Officer Brett P. Monia exercised 2,432 non-qualified stock options at an exercise price of $32.60 (transaction code M) and immediately sold the same 2,432 shares of common stock at $45.00 (transaction code S) pursuant to a Rule 10b5-1 plan adopted 08/13/24. Following the sale, Monia’s direct holdings stand at 179,820 common shares, while he retains 99,057 options outstanding. The options exercised were granted 01/03/23 and expire 01/02/32.

The sale represents roughly 1.4 % of his direct equity stake and appears routine given the pre-arranged trading plan. There is no indication of additional material events or changes to company fundamentals within the filing.

Positive

• Transaction conducted under a Rule 10b5-1 plan, indicating advance scheduling and reducing the likelihood of information-based trading.
• CEO retains 179,820 shares, maintaining significant alignment with shareholders.

Negative

• Net sale of 2,432 shares by the CEO, though modest, may be viewed as a slight negative sentiment signal.

Insights

Financial Analyst

TL;DR: Small, pre-planned CEO share sale—neutral signal for investors.

Monia converted 2,432 options into stock at $32.60 and sold them at $45, realising a ~$30k gross gain. Because the sale was executed under an established Rule 10b5-1 plan and equals only ~1.4 % of his 180k-share position, it does not materially alter insider ownership or suggest a directional view on Ionis fundamentals. No other derivatives were affected; 99,057 options remain. Overall, the filing is routine and should have minimal market impact.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2000	114180.00	187826153	08/01/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/01/2025	Stock Option Exercise	Issuer			2000	08/01/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
KIRA WAMPLER 500 3rd Street Ste 510 San Francisco CA 94107	Common	07/01/2025	2000	121920.00
KIRA WAMPLER 500 3rd Street Ste 510 San Francisco CA 94107	Common	06/02/2025	2000	105780.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Ionis (IONS) shares did the CEO sell?

Brett P. Monia sold 2,432 shares on 07/30/25 at $45.00 each.

What price did the CEO pay to exercise his stock options?

The exercise price was $32.60 per share.

Does the CEO still own Ionis stock after the sale?

Yes. He now directly owns 179,820 common shares plus 99,057 options.

Was the sale part of a 10b5-1 trading plan?

Yes. The filing states the sale was executed under a Rule 10b5-1 plan adopted on 08/13/24.

What percentage of the CEO's holdings was sold?

Approximately 1.4 % of his direct equity stake was sold.